当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.

Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.

Abstract：

:Myelodysplastic syndrome (MDS) in children is often considered as a variant of acute myeloid leukemia (AML) and frequently treated as such. However, there are very few reported data on the outcome following AML treatment. We analyzed 20 consecutive cases of de novo MDS treated in Denmark according to the NOPHO AML protocols. The results were compared with those obtained in 31 children with de novo AML treated with the same protocols, and with the outcome in 10 children with MDS who received allogeneic bone marrow transplantation (BMT) without prior AML therapy. Distinction between MDS and AML was made morphologically according to the FAB criteria. All children were followed for at least 37 months. The proportion of complete remission in MDS and AML was 35 percent vs 74 percent. (P = 0.005), resistant disease 25 percent vs 10 percent (P = 0.14), death in cytopenia 40 percent vs 16 percent (P= 0.06), and 3-year survival 15 percent vs 35 percent. (P = 0.11), respectively. Duration of treatment-related cytopenia was similar in MDS and AML, except for a longer period of leukopenia in MDS following the second course of induction. Seven of 10 MDS children receiving BMT without prior chemotherapy are long-term survivors. Our data suggest that conventional AML regimens are associated with a low rate of complete remission, a high risk of death in cytopenia, and a limited curative potential in childhood MDS. Allogeneic BMT was in contrast associated with a high survival rate. BMT may, at least in some patients, be performed successfully without prior induction chemotherapy. The different response to therapy in MDS and AML may reflect fundamental biological differences between the two conditions.

journal_name

Leukemia

journal_title

Leukemia

authors

Hasle H,Kerndrup G,Yssing M,Clausen N,Ostergaard E,Jacobsen N,Jacobsen BB

subject

Has Abstract

pub_date

1996-08-01 00:00:00

pages

1269-73

issue

8

eissn

0887-6924

issn

1476-5551

journal_volume

10

pub_type

临床试验,杂志文章

相关文献

LEUKEMIA文献大全
  • Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.

    abstract：:Novel approaches have been designed to treat leukemia based on our understanding of the genetic and biochemical lesions present in different malignancies. This meeting report summarizes some of the recent advances in leukemia treatment. Based on the discoveries of cellular oncogenes, chromosomal translocations, monocl...

    journal_title：Leukemia

    pub_type：

    doi：10.1038/sj.leu.2403156

    authors： Larson RA,Daley GQ,Schiffer CA,Porcu P,Pui CH,Marie JP,Steelman LS,Bertrand FE,McCubrey JA

    更新日期：2003-12-01 00:00:00

  • Molecular cloning of a 5' segment of the genomic phl gene defines a new breakpoint cluster region (bcr2) in Philadelphia-positive acute leukemias.

    abstract：:Molecular rearrangements of Ph1 chromosome, the hallmark of CML, are clustered in a 5.8-kb DNA segment, the so-called breakpoint cluster region (bcr) of the phl gene that is localized to chromosome 22q11. In Ph1-positive (Ph1+) ALLs, the rearrangements have been shown to involve either the 5.8-kb bcr (called bcr+) or ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Chen SJ,Chen Z,Grausz JD,Hillion J,d'Auriol L,Flandrin G,Larsen CJ,Berger R

    更新日期：1988-10-01 00:00:00

  • Successful short-term ex vivo expansion of NOD/SCID repopulating ability and CAFC week 6 from umbilical cord blood.

    abstract：:In view of the limited potential for rapid hematological recovery after transplantation of umbilical cord blood cells (UCB) in adults, we have attempted to expand CD34+ selected hemopoietic stem cells (HSC) and progenitors in 2-week cultures of whole graft pools in the presence or absence of serum and stromal layers, ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401917

    authors： Kusadasi N,van Soest PL,Mayen AE,Koevoet JL,Ploemacher RE

    更新日期：2000-11-01 00:00:00

  • Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.

    abstract：:Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods a...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2401559

    authors： Corradini P,Ladetto M,Pileri A,Tarella C

    更新日期：1999-11-01 00:00:00

  • Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.

    abstract：:An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to downregulate Bcl-2 and produce responses in a variety of malignancies including drug-resistant lymphoma. Incubation of ex vivo purified plasma cells from patients wit...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402768

    authors： van de Donk NW,Kamphuis MM,van Dijk M,Borst HP,Bloem AC,Lokhorst HM

    更新日期：2003-01-01 00:00:00

  • TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.

    abstract：:We previously reported the fusion of the TEL gene to the Syk gene in myelodysplastic syndrome with t(9;12)(q22;p12). TEL-Syk fusion transformed interleukin-3 (IL-3)-dependent murine hematopoietic cell line BaF3 to growth factor independence. Here, we investigate the intracellular signal transduction of the stable tran...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403266

    authors： Kanie T,Abe A,Matsuda T,Kuno Y,Towatari M,Yamamoto T,Saito H,Emi N,Naoe T

    更新日期：2004-03-01 00:00:00

  • Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma.

    abstract：:Primary effusion lymphoma (PEL) is a fatal malignancy, which typically presents as a lymphomatous effusion that later disseminates. Rapamycin (Rapa), which targets mTOR (mammalian target of Rapa), is currently evaluated as a treatment for PEL, but the recent development of PEL in Rapa-treated post-transplant recipient...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.117

    authors： Gasperini P,Tosato G

    更新日期：2009-10-01 00:00:00

  • B cells from bovine leukemia virus- (BLV) infected sheep with hematological disorders express the CD5 T cell marker.

    abstract：:Though peripheral blood B cells from healthy sheep were known to be devoid of the CD5 T cell marker, it appears from our study that most B cells from bovine leukemia virus- (BLV) infected sheep with hematological disorders express both the CD5 marker and surface IgM. The possible meaning of this T cell marker expressi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Letesson JJ,Mager A,Mammerickx M,Burny A,Depelchin A

    更新日期：1990-05-01 00:00:00

  • A paradigm shift in myelodysplastic syndromes.

    abstract：:A poorly defined transforming event(s) affects the pluripotential bone marrow (BM) stem cell in myelodysplastic syndromes (MDS), conferring a growth advantage upon it which leads eventually to monoclonal hematopoiesis. The progeny of this transformed ancestor undergo recognizable albeit dysplastic maturation. We propo...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Raza A,Mundle S,Shetty V,Alvi S,Chopra H,Span L,Parcharidou A,Dar S,Venugopal P,Borok R,Gezer S,Showel J,Loew J,Robin E,Rifkin S,Alston D,Hernandez B,Shah R,Kaizer H,Gregory S,Preisler H

    更新日期：1996-10-01 00:00:00

  • Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.

    abstract：:Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration subsequent to SCT may prevent relapse, but the role of scheduling and its impact on outcome are not known. In a prospective, randomized multicente...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/leu.2012.352

    authors： Pfeifer H,Wassmann B,Bethge W,Dengler J,Bornhäuser M,Stadler M,Beelen D,Vucinic V,Burmeister T,Stelljes M,Faul C,Dreger P,Kiani A,Schäfer-Eckart K,Schwerdtfeger R,Lange E,Kubuschok B,Horst HA,Gramatzki M,Brück P,S

    更新日期：2013-06-01 00:00:00

  • Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens.

    abstract：:Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SC...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404681

    authors： Jiménez M,Ercilla G,Martínez C

    更新日期：2007-08-01 00:00:00

  • HTLV-1-like particles and HTLV-1-related DNA sequences in an unambiguous case of Sèzary syndrome.

    abstract：:An unambiguous case of Sèzary syndrome associated with the presence of unusual retroviral infection markers is described. The blood smear showed 15% typical Sèzary cells but also rare atypical lymphocytes with convoluted nuclei, evocative of characteristic adult T-cell leukemia (ATL) flower cells. However, the patient...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Bazarbachi A,Saal F,Laroche L,Lasneret J,Gessain A,Daniel MT,Périès J

    更新日期：1994-01-01 00:00:00

  • Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.

    abstract：:We studied the differentiation profiles of B cell precursors (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the three major maturational BCP stages in BM. By correlating lineage-associated markers...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400732

    authors： Dworzak MN,Fritsch G,Fleischer C,Printz D,Fröschl G,Buchinger P,Mann G,Gadner H

    更新日期：1997-08-01 00:00:00

  • Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL.

    abstract：:Acute myelogenous leukemia (AML) remains a deadly disease for most adult patients, due primarily to the emergence of chemoresistant cells. Defects in apoptosis pathways make important contributions to chemoresistance, suggesting a need to restore apoptosis sensitivity or to identify alternative pathways for apoptosis ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403112

    authors： Suh WS,Kim YS,Schimmer AD,Kitada S,Minden M,Andreeff M,Suh N,Sporn M,Reed JC

    更新日期：2003-11-01 00:00:00

  • Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.

    abstract：:Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In uni...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.109

    authors： Blum KA,Ruppert AS,Woyach JA,Jones JA,Andritsos L,Flynn JM,Rovin B,Villalona-Calero M,Ji J,Phelps M,Johnson AJ,Grever MR,Byrd JC

    更新日期：2011-09-01 00:00:00

  • Detection of additional JH/BCL2 translocations in follicular lymphoma.

    abstract：:In vitro enzymatic amplification and direct sequencing were used to detect and characterize t(14;18) recombination junctions in peripheral blood and bone marrow mononuclear cell preparations from patients with follicular lymphoma in remission. Samples from 24/44 patients were found to be positive for translocations in...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Price CG,Tuszynski A,Watt SM,Murdoch SJ,Lister TA,Young BD

    更新日期：1991-07-01 00:00:00

  • STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.

    abstract：:Nasal-type natural killer (NK) cell lymphoma is an infrequent aggressive malignant disease with very poor prognosis. We aimed to explore the possible role of the transcription factor STAT3 in the pathophysiology of this malignancy, as it was involved in oncogenesis and chemoresistance. For this, we established and cha...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.91

    authors： Coppo P,Gouilleux-Gruart V,Huang Y,Bouhlal H,Bouamar H,Bouchet S,Perrot C,Vieillard V,Dartigues P,Gaulard P,Agbalika F,Douay L,Lassoued K,Gorin NC

    更新日期：2009-09-01 00:00:00

  • Cytokine enhancement of immunogenicity in chronic myeloid leukaemia.

    abstract：:Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic respon...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400858

    authors： Coleman S,Throp D,Fisher J,Bailey-Wood R,Lim SH

    更新日期：1997-12-01 00:00:00

  • Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells.

    abstract：:Recent work suggests that chronic lymphocytic leukemia (B-CLL) expressing unmutated immunoglobulin V genes could correspond to the proliferation of naive B cells whereas those expressing mutated genes, may correspond to the proliferation of post-germinal center B cells. Current data from gene profiling expression have...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402731

    authors： Oppezzo P,Magnac C,Bianchi S,Vuillier F,Tiscornia A,Dumas G,Payelle-Brogard B,Ajchenbaum-Cymbalista F,Dighiero G,Pritsch O

    更新日期：2002-12-01 00:00:00

  • Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.

    abstract：:One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose thera...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Carella Am,Carlier P,Congiu A,Occhini D,Meloni G,Anselmo AP,Mandelli F,Mazza P,Tura S,Mangoni L

    更新日期：1991-01-01 00:00:00

  • Cell-free transmission of Fv-4 resistance gene product controlling Friend leukemia virus-induced leukemogenesis in mice.

    abstract：:Fv-4 is a mouse gene that dominantly confers resistance to infection by ecotropic murine leukemia virus (MuLV). The Fv-4' env antigen that binds to the cell surface of Fv-4'-bearing C3H cells was found in sera from normal Fv-4'-bearing C4W mice. The serum Fv-4' env antigen binds to ecotropic MuLV receptors, shown by s...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Kitagawa M,Aizawa S,Ikeda H,Hirokawa K

    更新日期：1997-04-01 00:00:00

  • Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.

    abstract：:We have studied the plasma pharmacokinetics of idarubicin (4-demethoxy daunorubicin) in 11 elderly patients suffering from acute myeloblastic leukemia receiving orally 30 mg/m2 per day for 3 consecutive days. Idarubicin culminated in plasma 4 hr after administration and followed three similar time courses after the th...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Robert J,Rigal-Huguet F,Huet S,Pris J,Hurteloup P

    更新日期：1990-03-01 00:00:00

  • Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

    abstract：:In acute myeloid leukemia (AML), assessment of minimal residual disease (MRD) by flow cytometry (flow MRD) after induction and consolidation therapy has been shown to provide independent prognostic information. However, data on the value of earlier flow MRD assessment are lacking. Therefore, the value of flow MRD dete...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.186

    authors： Köhnke T,Sauter D,Ringel K,Hoster E,Laubender RP,Hubmann M,Bohlander SK,Kakadia PM,Schneider S,Dufour A,Sauerland MC,Berdel WE,Büchner T,Wörmann B,Braess J,Hiddemann W,Spiekermann K,Subklewe M

    更新日期：2015-02-01 00:00:00

  • Mesenchymal stromal cells inhibit proliferation of virus-specific CD8(+) T cells.

    abstract：:Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in g...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.273

    authors： Malcherek G,Jin N,Hückelhoven AG,Mani J,Wang L,Gern U,Diehlmann A,Wuchter P,Schmitt A,Chen B,Ho AD,Schmitt M

    更新日期：2014-12-01 00:00:00

  • AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.

    abstract：:Despite improved prognosis in acute myelogenous leukaemia (AML) children with Down syndrome (DS), therapy-related toxicity remained a problem. We compared 67 DS patients from study AML-BFM 98 with 51 DS patients of the previous study AML-BFM 93, and the non-DS groups of both studies. Compared to non-DS patients, DS pa...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.leu.2403814

    authors： Creutzig U,Reinhardt D,Diekamp S,Dworzak M,Stary J,Zimmermann M

    更新日期：2005-08-01 00:00:00

  • A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.

    abstract：:Inorganic arsenic trioxide (As(2)O(3)) is a highly effective treatment for acute promyelocytic leukemia (APL). However, other cancers do not respond well to this form of arsenic at clinically achievable doses. We tested a novel arsenical, S-dimethylarsino-glutathione (darinaparsin) for efficacy in various malignancies...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.194

    authors： Diaz Z,Mann KK,Marcoux S,Kourelis M,Colombo M,Komarnitsky PB,Miller WH Jr

    更新日期：2008-10-01 00:00:00

  • Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

    abstract：:In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2014.60

    authors： Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

    更新日期：2014-08-01 00:00:00

  • Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.

    abstract：:We previously identified autoantibodies to the endocytic-associated protein Huntingtin-interacting protein 1-related (HIP1R) in diffuse large B-cell lymphoma (DLBCL) patients. HIP1R regulates internalization of cell surface receptors via endocytosis, a process relevant to many therapeutic strategies including CD20 tar...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.224

    authors： Wong KK,Gascoyne DM,Brown PJ,Soilleux EJ,Snell C,Chen H,Lyne L,Lawrie CH,Gascoyne RD,Pedersen LM,Møller MB,Pulford K,Murphy D,Green TM,Banham AH

    更新日期：2014-02-01 00:00:00

  • Targeting MYC in multiple myeloma.

    abstract：:Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC locus and deregulation of upstream pathways such as IRF4, DIS3/LIN28B/...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-018-0036-x

    authors： Jovanović KK,Roche-Lestienne C,Ghobrial IM,Facon T,Quesnel B,Manier S

    更新日期：2018-06-01 00:00:00

  • Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.

    abstract：:Current MRD studies in T-cell acute lymphoblastic leukemia (T-ALL) mainly use T-cell receptor gamma, delta and SIL-TAL1 gene rearrangements as MRD-PCR targets. However, low frequency or limited diversity of these markers restricts the number of evaluable patients, particularly because two markers are recommended for M...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403263

    authors： Brüggemann M,van der Velden VH,Raff T,Droese J,Ritgen M,Pott C,Wijkhuijs AJ,Gökbuget N,Hoelzer D,van Wering ER,van Dongen JJ,Kneba M

    更新日期：2004-04-01 00:00:00